Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis surve...

por van de Kerkhof, P.C.M., Reich, K., Kavanaugh, A., Bachelez, H., Barker, J., Girolomoni, G., Langley, R.G., Paul, C.F., Puig, L., Lebwohl, M.G.
Publicado 2015

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

por Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.
Publicado 2020

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

por Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.
Publicado 2021

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, doubl...

por Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.
Publicado 2020

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded t...

por Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.
Publicado 2020